Change comes after initial data from company's study finds 2-4 year olds didn't respond as expected to very low-dose shots; no safety issues found

Pharma giant also says full study results confirm medication reduces combined hospitalizations and deaths by about 89% among high-risk adults

New variant appears to cause less severe illness than previous versions of coronavirus, but seems to be more easily transmitted and is better at evading vaccines

Researchers looked at data of over 840,000 people who got booster; paper co-author says study 'unequivocally' shows value of extra dose against Delta strain

Vaccine producer says it is working on a shot specifically designed for the variant that is slated to be ready in March

Albert Bourla says new shot may be needed if testing shows existing vaccine provides less protection against new coronavirus variant

No serious safety concerns seen in individuals with at least 6 months of follow-up after 2nd dose; pharma giant says data will help support application for full approval

Drug company CEO Albert Bourla says it is 'moving as quickly as possible' to get the treatment into the hands of patients

Move could make treatment available to more than half the world’s population, by allowing generic drug companies to produce the pill cheaply in 95 low- and middle-income nations

PM and health minister reach agreement with drug company for 'tens of thousands of doses'; initial data shows almost 90% efficacy